Optimising bone health in survivors of breast cancer
- PMID: 17267320
- DOI: 10.1016/S1470-2045(07)70007-4
Optimising bone health in survivors of breast cancer
Comment on
-
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.Lancet Oncol. 2007 Feb;8(2):119-27. doi: 10.1016/S1470-2045(07)70003-7. Lancet Oncol. 2007. PMID: 17267326 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical